Materials • Major Chemicals
$66.53 ▼ -1.40
(-2.06%)
MKT CAP: $7.61B • VOL: 1.80M
52W L $56 52W H $83
EMN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $8.75B | $9.38B | $9.21B |
| YoY Revenue Growth % | -6.7% | +1.9% | — |
| Gross Profit | $1.84B | $2.29B | — |
| Gross Margin % | 21.1% | 24.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $559.3M | $1.07B | $1.05B |
| Operating Margin % | 6.4% | 11.4% | 11.5% |
| Net Income (GAAP) | $474.0M | $905.0M | $894.0M |
| EBITDA (Normalized) | $996.1M | $1.55B | $1.39B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $970.0M | $1.29B | $1.37B |
| Capital Expenditures (CapEx) | $546.0M | $599.0M | $414.4M |
| Free Cash Flow (FCF) | $424.0M | $688.0M | $959.5M |
| FCF Margin % | 4.8% | 7.3% | 10.4% |
| Return on Invested Capital (ROIC %) | 4.6% | 8.9% | 12.5% |
| Cash & Short-Term Equivalents | $566.0M | $837.0M | — |
| Total Debt (Short + Long Term) | $4.20B | $4.57B | $2.59B |
| Total Stockholders' Equity | $5.96B | $5.78B | $5.30B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR EMN.